Register to attend a free NIH webinar. Attendees will learn about a new non-opioid small molecule for treating Opioid Use and Substance Use Disorders by selectively targeting the Dopamine D3 receptor. Dr. Amy Newman and her team at the National Institutes of Health’s National Institute on Drug Abuse (NIDA), along with researchers from the National Center for Advancing Translational Sciences (NCATS), discovered this new molecule and have advanced its development toward an upcoming clinical trial, to also include an Investigative New Drug (IND) designation.
Events
NIH Technology Opportunity Webinar: Novel Small Molecule Targeting the Dopamine D3 Receptor for Treating Opioid and Other Substance Use Disorders
